Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of “Hold” from Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH) has received an average rating of “Hold” from the fourteen analysts that are covering the stock, MarketBeat.com reports. Nine analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $108.1111.

LNTH has been the topic of a number of recent analyst reports. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Mizuho decreased their target price on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 29th. Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. TD Cowen downgraded shares of Lantheus from a “buy” rating to a “hold” rating and cut their price target for the company from $110.00 to $102.50 in a report on Monday, August 3rd. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $115.00 price objective on shares of Lantheus in a research note on Monday, June 29th.

Lantheus Price Performance

Shares of LNTH opened at $100.68 on Wednesday. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. The stock’s 50 day moving average is $104.25 and its two-hundred day moving average is $88.63. Lantheus has a twelve month low of $49.67 and a twelve month high of $111.86. The firm has a market capitalization of $6.57 billion, a PE ratio of 24.32 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. The business had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.57 EPS. Research analysts anticipate that Lantheus will post 4.5 earnings per share for the current year.

Institutional Investors Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently modified their holdings of LNTH. Western Wealth Management LLC purchased a new stake in shares of Lantheus during the 1st quarter worth approximately $25,000. Osterweis Capital Management Inc. purchased a new position in Lantheus in the 2nd quarter valued at approximately $36,000. Allworth Financial LP purchased a new position in Lantheus in the 2nd quarter valued at approximately $49,000. Smartleaf Asset Management LLC raised its holdings in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the last quarter. Finally, Bessemer Group Inc. boosted its position in Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 354 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.